The initiation of prostate cancer and the progression of the disease are driven by androgen receptor (AR) signalling, and androgen deprivation therapy (ADT) constitutes the backbone of systemic therapy for patients with advanced disease. The gene discussed is AR; the disease is prostate cancer.